SAFETY DATA SHEET

Ezetimibe / Rosuvastatin Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe / Rosuvastatin Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 26 Talavera Road, Talavera Corp Centre, Macquarie Park
New South Wales, 2113 Australia
Telephone : (61)-02-8988-8000
Emergency telephone number : (61)-02-8988-8000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Carcinogenicity : Category 1B
Reproductive toxicity : Category 1B
Specific target organ toxicity - single exposure (Oral) : Category 2 (Liver, Kidney, muscle)
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

GHS label elements
Hazard pictograms : ☢️
Signal word : Danger
Hazard statements : H350 May cause cancer.
H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Liver, Kidney, muscle) if swallowed.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P281 Use personal protective equipment as required.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Components</strong></td>
<td></td>
</tr>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>147098-20-2</td>
</tr>
<tr>
<td>Sodium n-dodecyl sulfate</td>
<td>151-21-3</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed:
- May cause cancer.
- May damage fertility. May damage the unborn child.
- May cause damage to organs if swallowed.
- May cause damage to organs through prolonged or repeated exposure if swallowed.
- Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
- Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Fluorine compounds
- Nitrogen oxides (NOx)
- Sulphur oxides
- Metal oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Hazchem Code:
2Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces...
### SECTION 7. HANDLING AND STORAGE

| Technical measures | Static electricity may accumulate and ignite suspended dust causing an explosion.  
|                    | Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | Do not get on skin or clothing.  
|                        | Do not breathe dust.  
|                        | Do not swallow. |
|                        | Avoid contact with eyes. |
|                        | Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment |
|                        | Keep container tightly closed. |
|                        | Minimize dust generation and accumulation. |
|                        | Keep container closed when not in use. |
|                        | Keep away from heat and sources of ignition. |
|                        | Take precautionary measures against static discharges. |
|                        | Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. |
|                    | When using do not eat, drink or smoke. |
|                    | Wash contaminated clothing before re-use. |
|                    | The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | Keep in properly labelled containers. |
|                        | Store locked up. |
|                        | Keep tightly closed. |
|                        | Store in accordance with the particular national regulations. |
| Materials to avoid | Do not store with the following product types: |
|                    | Strong oxidizing agents |

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters
### Components

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>147098-20-2</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Further information:** This value is for inhalable dust containing no asbestos and < 1% crystalline silica

### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

**Respiratory protection**

- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**

- Particulates type

**Hand protection**

- Chemical-resistant gloves

**Eye protection**

- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Ezetimibe / Rosuvastatin Formulation

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg
LD50 (Dog): > 3,000 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available
Acute toxicity (other routes of) : LD50 (Rat): > 2,000 mg/kg
**SAFETY DATA SHEET**

**Ezetimibe / Rosuvastatin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue: 24.04.2019</th>
<th>Date of first issue: 18.09.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.4</td>
<td>09/13/2019</td>
<td>3177573-00005</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Application Route: Intraperitoneal</th>
</tr>
</thead>
<tbody>
<tr>
<td>LD50 (Mouse): &gt; 1,000 - &lt; 2,000 mg/kg</td>
</tr>
<tr>
<td>Application Route: Intraperitoneal</td>
</tr>
</tbody>
</table>

**Rosuvastatin:**

<table>
<thead>
<tr>
<th>Acute oral toxicity</th>
<th>LD50 (Rat): &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Organs: Liver, Stomach, muscle, Kidney</td>
<td></td>
</tr>
</tbody>
</table>

**Sodium n-dodecyl sulfate:**

<table>
<thead>
<tr>
<th>Acute oral toxicity</th>
<th>LD50 (Rat): 1,200 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method: OECD Test Guideline 401</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute dermal toxicity</th>
<th>LD50 (Rat): &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method: OECD Test Guideline 402</td>
<td></td>
</tr>
<tr>
<td>Remarks: Based on data from similar materials</td>
<td></td>
</tr>
</tbody>
</table>

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Acute oral toxicity</th>
<th>LD50 (Rat): &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method: OECD Test Guideline 423</td>
<td></td>
</tr>
<tr>
<td>Assessment: The substance or mixture has no acute oral toxicity</td>
<td></td>
</tr>
<tr>
<td>Remarks: Based on data from similar materials</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute dermal toxicity</th>
<th>LD50 (Rabbit): &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remarks: Based on data from similar materials</td>
<td></td>
</tr>
</tbody>
</table>

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Ezetimibe:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Sodium n-dodecyl sulfate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Skin irritation</td>
</tr>
</tbody>
</table>

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**Serious eye damage/eye irritation**

Not classified based on available information.
Components:

Ezetimibe:
Species: Rabbit
Result: No eye irritation

Sodium n-dodecyl sulfate:
Species: Rabbit
Result: Irreversible effects on the eye
Method: OECD Test Guideline 405

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Components:

Ezetimibe:
Test Type: Maximisation Test
Species: Guinea pig
Result: negative

Sodium n-dodecyl sulfate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Magnesium stearate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Chronic toxicity
Germ cell mutagenicity
Not classified based on available information.
Components:

**Cellulose:**

- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
  - Test Type: In vitro mammalian cell gene mutation test Result: negative

- Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

**Ezetimibe:**

- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) MEp type: with and without metabolic activation Result: negative
  - Test Type: Chromosomal aberration
  - Test system: Human lymphocytes
  - Result: negative

- Genotoxicity in vivo: Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

**Rosuvastatin:**

- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  - Test system: Escherichia coli
  - Result: negative

  - Test Type: Chromosomal aberration
  - Test system: Chinese hamster lung cells
  - Result: negative

- Genotoxicity in vivo: Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Ingestion
  - Result: negative

**Sodium n-dodecyl sulfate:**

- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  - Method: OECD Test Guideline 471
  - Result: negative

  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
Genotoxicity in vivo: Test Type: Rodent dominant lethal test (germ cell) (in vivo)
Species: Mouse
Application Route: Ingestion
Result: negative

Magnesium stearate:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
May cause cancer.

Components:

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Ezetimibe:
Species: Rat, female
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Rat, male
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Mouse
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Rosuvastatin:
Species: Rat
Application Route: Oral
Exposure time: 104 weeks
LOAEL: 80 mg/kg body weight
Result: positive
Symptoms: Tumour
Target Organs: Uterus (including cervix)
Species: Mouse
Application Route: Oral
Exposure time: 107 weeks
LOAEL: 200 mg/kg body weight
Result: positive
Symptoms: liver adenoma, carcinoma
Target Organs: Liver

Sodium n-dodecyl sulfate:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative

Effects on foetal development: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

Ezetimibe:
Effects on fertility: Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1,000 mg/kg body weight Result: No effects on fertility, No fetotoxicity

Effects on foetal development: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight Result: No adverse effects

Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight Result: No adverse effects
### Rosuvastatin:

- **Effects on fertility**
  - Test Type: Fertility  
  - Species: Rat  
  - Application Route: Oral  
  - Fertility: NOAEL: 50 mg/kg body weight
  
  - Test Type: Fertility  
  - Species: Monkey  
  - Application Route: Oral  
  - Fertility: LOAEL: 30 mg/kg body weight  
  - Result: Effects on male and female reproductive organs.

- **Effects on foetal development**
  - Test Type: Development  
  - Species: Rat  
  - Application Route: Oral  
  - Developmental Toxicity: LOAEL: 50 mg/kg body weight  
  - Result: foetal mortality
  
  - Test Type: Development  
  - Species: Rabbit  
  - Application Route: Oral  
  - Developmental Toxicity: LOAEL: 3 mg/kg body weight  
  - Result: foetal mortality, Maternal toxicity observed.

- **Reproductive toxicity - Assessment**
  - May damage fertility. May damage the unborn child.

### Sodium n-dodecyl sulfate:

- **Effects on fertility**
  - Test Type: Two-generation reproduction toxicity study  
  - Species: Rat  
  - Application Route: Ingestion  
  - Method: OECD Test Guideline 416  
  - Result: negative  
  - Remarks: Based on data from similar materials

- **Effects on foetal development**
  - Test Type: Embryo-foetal development  
  - Species: Rat  
  - Application Route: Ingestion  
  - Result: negative  
  - Remarks: Based on data from similar materials

### Magnesium stearate:

- **Effects on fertility**
  - Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
  - Species: Rat  
  - Application Route: Ingestion  
  - Method: OECD Test Guideline 422  
  - Result: negative  
  - Remarks: Based on data from similar materials

- **Effects on foetal development**
  - Test Type: Embryo-foetal development  
  - Species: Rat  
  - Application Route: Ingestion  
  - Result: negative
STOT - single exposure
May cause damage to organs (Liver, Kidney, muscle) if swallowed.

Components:
Rosuvastatin:
Exposure routes : Oral
Target Organs : Liver, Kidney, muscle
Assessment : Causes damage to organs.

STOT - repeated exposure
May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Components:
Rosuvastatin:
Exposure routes : Oral
Target Organs : Eye
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Cellulose:
Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ezetimibe:
Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 1,500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Dog
### Ezetimibe / Rosuvastatin Formulation

<table>
<thead>
<tr>
<th>Substance</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe</td>
<td>300 mg/kg</td>
<td>Oral</td>
<td>1 yr</td>
<td></td>
<td></td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Rosuvastatin:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>90 mg/kg</td>
<td>Oral</td>
<td></td>
<td>Brain</td>
<td>Oedema, Blood disorders, Necrosis</td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td>24 Days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>6 mg/kg</td>
<td>Oral</td>
<td>52 Weeks</td>
<td>Cornea</td>
<td>Corneal opacity</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>30 mg/kg</td>
<td>Oral</td>
<td>12 Weeks</td>
<td>Eye</td>
<td>Eye disease</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>90 mg/kg</td>
<td>Oral</td>
<td>4 Weeks</td>
<td>eye - retina</td>
<td>Eye disease</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium n-dodecyl sulfate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Rat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>488 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
<td></td>
<td></td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>Magnesium stearate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species</td>
<td>Rat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
<td></td>
<td></td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>
Aspiration toxicity
Not classified based on available information.

Components:

Ezetimibe:
Not applicable

Experience with human exposure

Components:

Ezetimibe:
Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Rosuvastatin:
Ingestion : Target Organs: Kidney
Symptoms: kidney toxicity
Remarks: Based on Human Evidence
Target Organs: muscle
Symptoms: musculoskeletal pain
Remarks: Based on Human Evidence
Target Organs: Liver
Symptoms: liver function change
Remarks: Based on Human Evidence

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ezetimibe:
Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

NOEC (Daphnia magna (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms:

EC50: > 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Rosuvastatin:

Toxicity to fish:

LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l
Exposure time: 96 hrs
Method: FDA 4.11

LC50 (Lepomis macrochirus (Bluegill sunfish)): > 1,000 mg/l
Exposure time: 96 hrs
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates:

EC50 (Daphnia magna (Water flea)): 63 mg/l
Exposure time: 48 hrs
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:

EC50 (Microcystis aeruginosa (blue-green algae)): > 640 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

NOEC (Microcystis aeruginosa (blue-green algae)): 330 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

EC50 (Pseudokirchneriella subcapitata (green algae)): > 800
### SAFETY DATA SHEET

**Ezetimibe / Rosuvastatin Formulation**

**Version** 1.4  
**Revision Date:** 09/13/2019  
**SDS Number:** 3177573-00005  
**Date of last issue:** 24.04.2019  
**Date of first issue:** 18.09.2018

<table>
<thead>
<tr>
<th>Substance</th>
<th>Toxicity to fish (Chronic toxicity)</th>
<th>NOEC</th>
<th>Exposure time (hrs)</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium n-dodecyl sulfate</td>
<td>NOEC (Pimephales promelas (fathead minnow)): 0.18 mg/l</td>
<td>EC50: &gt; 100 mg/l</td>
<td>3</td>
<td>OECD Test Guideline 209</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>LC50 (Leuciscus idus (Golden orfe)): &gt; 100 mg/l</td>
<td>EC50: 135 mg/l</td>
<td>3</td>
<td>DIN 38412</td>
</tr>
</tbody>
</table>

**Exposure time:**
- 96 hrs
- 32 Days
- 21 Days
- 3 hrs
- 72 h
- 42 d
- 7 d
- 3 h

**Method:**
- FDA 4.01
- OECD Test Guideline 210
- OECD Test Guideline 211
- OECD Test Guideline 209
- OECD Test Guideline 209
- DIN 38412
Toxicity to daphnia and other aquatic invertebrates:

- **EL50 (Daphnia magna (Water flea)):** > 1 mg/l
  - Exposure time: 47 h
  - Test substance: Water Accommodated Fraction
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility

Toxicity to algae/aquatic plants:

- **EL50 (Pseudokirchneriella subcapitata (green algae)):** > 1 mg/l
  - Exposure time: 72 h
  - Test substance: Water Accommodated Fraction
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility

  **NOELR (Pseudokirchneriella subcapitata (green algae)):** > 1 mg/l
  - Exposure time: 72 h
  - Test substance: Water Accommodated Fraction
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials

Toxicity to microorganisms:

- **EC10 (Pseudomonas putida):** > 100 mg/l
  - Exposure time: 16 h
  - Test substance: Water Accommodated Fraction
  - Remarks: Based on data from similar materials

Persistence and degradability

**Components:**

**Cellulose:**
- **Biodegradability:** Result: Readily biodegradable.

**Ezetimibe:**
- **Biodegradability:** Result: Not readily biodegradable.
  - Biodegradation: 6.8 %
  - Exposure time: 28 d

**Stability in water:**
- Hydrolysis: 50 % (4.5 d)
  - Method: OECD Test Guideline 111

**Rosuvastatin:**
- **Biodegradability:** Biodegradation: < 10 %
  - Exposure time: 28 Days
  - Method: OECD Test Guideline 301F
  - Remarks: Not inherently biodegradable.

**Stability in water:**
- Hydrolysis: < 10 % (5 Days)

**Sodium n-dodecyl sulfate:**
Biodegradability: Result: Readily biodegradable.
Biodegradation: 95% 
Exposure time: 28 d 
Method: OECD Test Guideline 301B

Magnesium stearate:
Biodegradability: Result: Not biodegradable 
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Ezetimibe:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173 
Exposure time: 97 d 
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.36

Rosuvastatin:
Partition coefficient: n-octanol/water: log Pow: 0.3

Sodium n-dodecyl sulfate:
Partition coefficient: n-octanol/water: log Pow: 0.83

Magnesium stearate:
Partition coefficient: n-octanol/water: log Pow: > 4

Mobility in soil

Components:

Ezetimibe:
Distribution among environmental compartments: log Koc: 4.35 
Method: OECD Test Guideline 106

Rosuvastatin:
Distribution among environmental compartments: log Koc: 2.15 
Method: FDA 3.08

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin)
- Class: 9
- Packing group: III
- Labels: 9

**IATA-DGR**
- UN/ID No.: UN 3077
- Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Rosuvastatin)
- Class: 9
- Packing group: III
- Labels: Miscellaneous
- Packing instruction (cargo aircraft): 956
- Packing instruction (passenger aircraft): 956
- Environmentally hazardous: yes

**IMDG-Code**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin)
- Class: 9
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F
- Marine pollutant: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
- Not applicable for product as supplied.

**National Regulations**

**ADG**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin)
- Class: 9
- Packing group: III
- Labels: 9
- Hazchem Code: 2Z
Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely
based upon the properties of the unpackaged material as it is described within this Safety Data
Sheet. Transportation classifications may vary by mode of transportation, package sizes, and var-
iations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mix-
ture

Prohibition/Licensing Requirements : There is no applicable prohibition or
notification/licensing requirements, including for carcinogens under
Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information
Revision Date : 09/13/2019
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Con-
taminants.
ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-
tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and
SAFETY DATA SHEET

Ezetimibe / Rosuvastatin Formulation

Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN